← Back to Blog
capsules

Low Dose Naltrexone for Inflammatory Bowel Disease

Many chronic conditions can potentially benefit from the use of low dose naltrexone (LDN). We have already discussed some of these applications on our blog including psoriasis and rheumatoid arthritis. Recent studies have found positive results when LDN is used to treat inflammatory bowel disease (IBD). For many patients, current treatments for IBD do not work or lose effectiveness over time. LDN was investigated as a long-term treatment option because…
Read Full Article
Low Dose Naltrexone (LDN) Capsules

What is LDN?

Key Points LDN is a lower dose of the FDA-approved drug naltrexone, which has been used for many years to treat opioid addiction. Evidence continues to grow that LDN can be an effective treatment for a variety of conditions including Crohn’s, lupus, fibromyalgia, and multiple sclerosis. LDN can only be obtained from a compounding pharmacy since the lower dosages of naltrexone are not FDA-approved. LDN Advantages Low cost: LDN is…
Read Full Article
mortar and pestle

Low Dose Naltrexone for Crohn’s Disease

Low Dose Naltrexone (LDN) is a drug that can provide therapeutic benefits for many chronic conditions. LDN refers to a lower dose of the FDA-approved drug naltrexone – an opioid antagonist used to treat opioid addiction. Opioid antagonists have been shown to improve healing and tissue repair. LDN has both anti-inflammatory and immunological effects and is used by doctors to treat symptoms of inflammation throughout the body. Crohn’s disease has…
Read Full Article

Low Dose Naltrexone and Chronic Illness

Low dose naltrexone (LDN) is a promising treatment with the potential to help a variety of conditions and improve the immune system. While it is still being studied, there is growing evidence that this prescription medication can help with several chronic illnesses. Naltrexone was approved by the FDA in 1984 for the treatment of opioid addiction. “Low Dose” Naltrexone refers to the use of a dosage that is much lower…
Read Full Article